Loading institutional data...
Loading institutional data...
Held by 226 of 5,944 reporting institutions (92th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $606.9M 100.0% | $713.1M 100.0% | $863.5M 100.0% | $1.00B 100.0% | $1.77B 100.0% | $1.44B 100.0% | $901.9M 100.0% | $990.3M 100.0% | $966.0M 100.0% | $1.12B 100.0% |
| Cost of Revenue | $400.9M 66.1% | $494.6M 69.4% | $545.4M 63.2% | $716.0M 71.3% | — | — | — | — | $61.2M 6.3% | $564.1M 50.5% |
| Cost of Products | — | — | — | — | — | — | — | — | $61.2M 6.3% | $47.4M 4.2% |
| Cost of Services | — | — | — | — | — | — | — | — | $559.0M 57.9% | $564.1M 50.5% |
| Gross Profit | $205.9M 33.9% | $218.5M 30.6% | $318.1M 36.8% | $288.2M 28.7% | — | — | — | — | — | — |
| Research & Development | $124.0M 20.4% | $105.2M 14.8% | $89.6M 10.4% | $73.9M 7.4% | $76.8M 4.3% | $75.3M 5.2% | $117.9M 13.1% | $125.6M 12.7% | $126.4M 13.1% | $113.9M 10.2% |
| Selling, General & Admin | $223.0M 36.7% | $304.2M 42.7% | $300.6M 34.8% | $372.7M 37.1% | $468.9M 26.4% | $355.6M 24.8% | $343.3M 38.1% | $358.3M 36.2% | $414.6M 42.9% | $407.3M 36.5% |
| Total Operating Expenses | $724.3M 119.3% | $865.2M 121.3% | $1.02B 118.2% | $1.23B 122.5% | $1.76B 98.9% | $1.38B 96.0% | $1.18B 130.4% | $1.16B 117.3% | $1.24B 128.6% | $1.21B 108.6% |
| Operating Income | -$117.4M -19.3% | -$152.1M -21.3% | -$157.0M -18.2% | -$226.3M -22.5% | $18.8M 1.1% | $57.7M 4.0% | -$274.1M -30.4% | -$171.2M -17.3% | -$276.4M -28.6% | -$96.6M -8.6% |
| Interest Expense | $0 0.0% | $47.5M 6.7% | $13.5M 1.6% | $12.1M 1.2% | $18.9M 1.1% | — | — | — | — | — |
| Interest & Investment Income | $14.8M 2.4% | $8.4M 1.2% | $4.0M 0.5% | $2.0M 0.2% | $28K 0.0% | — | — | — | — | — |
| Other Income (Expense), net | -$124.0M -20.4% | $141.7M 19.9% | -$27.3M -3.2% | -$165.3M -16.5% | -$32.8M -1.8% | -$9.0M -0.6% | -$30.9M -3.4% | -$6.1M -0.6% | $4.5M 0.5% | -$271K -0.0% |
| Pretax Income | -$241.4M -39.8% | -$10.4M -1.5% | -$184.3M -21.3% | -$391.5M -39.0% | -$14.0M -0.8% | $48.7M 3.4% | -$305.0M -33.8% | -$177.3M -17.9% | -$271.9M -28.1% | -$96.8M -8.7% |
| Income Tax Expense | -$15.7M -2.6% | $42.8M 6.0% | $4.4M 0.5% | -$63.5M -6.3% | $15.5M 0.9% | $17.6M 1.2% | $7.1M 0.8% | -$38.7M -3.9% | $18.9M 2.0% | -$56.1M -5.0% |
| Net Income | -$225.68B -37187.0% | -$53.22B -7463.3% | -$188.86B -21871.9% | -$328.40B -32703.3% | -$30.14B -1698.5% | $30.6M 2.1% | -$314.9M -34.9% | -$153.0M -15.5% | -$305.3M -31.6% | -$48.4M -4.3% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.30 | $-0.08 | $-0.25 | $-0.46 | $-0.05 | $0.05 | $-0.53 | $-0.27 | $-0.55 | $-0.09 |
| EPS (Diluted) | $-0.30 | $-0.08 | $-0.25 | $-0.46 | $-0.05 | $0.05 | $-0.53 | $-0.27 | $-0.55 | $-0.10 |
| Weighted Avg Shares (Basic) | 751.1M | 694.0M | 751.8M | 719.1M | 648.1M | 640.7M | 595.5M | 563.1M | 559.2M | 550.8M |
| Weighted Avg Shares (Diluted) | 751.1M | 694.0M | 751.8M | 719.1M | 648.1M | 640.7M | 595.5M | 563.1M | 559.2M | 555.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $47M buybacks = $47M returned on -$191M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -14%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~5.4% on $874M of debt. Interest last disclosed in FY2024 (no longer broken out).
Cash of $364M fully covers short-term debt of $2M.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| OPK | $1.2B | — | — | 2.0× | -14.9% | 33.9% | -37.2% | -17.8% | -14.0% | -13.4× | 226 |
Peers = companies sharing OPK's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
No standout strengths flagged.
Where each multiple sits in its own 14-yr range · 64th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 1.5× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | — | — | — | 71.3 | 63.2 | 69.4 | 66.1 |
| Gross Profit | — | — | — | — | 28.7 | 36.8 | 30.6 | 33.9 |
| R&D | 12.7 | 13.1 | 5.2 | 4.3 | 7.4 | 10.4 | 14.8 | 20.4 |
| SG&A | 36.2 | 38.1 | 24.8 | 26.4 | 37.1 | 34.8 | 42.7 | 36.7 |
| Operating Income | -17.3 | -30.4 | 4.0 | 1.1 | -22.5 | -18.2 | -21.3 | -19.3 |
| Income Tax | -3.9 | 0.8 | 1.2 | 0.9 | -6.3 | 0.5 | 6.0 | -2.6 |
| Net Income | -15.5 | -34.9 | 2.1 | -1698.5 | -32703.3 | -21871.9 | -7463.3 | -37187.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on OPK: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.